H.C. Wainwright lowered the firm’s price target on Biora Therapeutics to $15 from $50 and keeps a Buy rating on the shares. The analyst cites the company’s recent equity raises for the target drop. The firm says the initial SAD data reaffirm NaviCap’s mechanism of action and further de-risk the upcoming clinical readout.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOR:
- Biora Therapeutics announces interim results of BT-600 clinical trial
- Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
- Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Biora Therapeutics prices 5.45M shares at $1.10 in registered direct offering
- Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
